EYLEA® 8mg Safety Profile

Safety profile

The reassurance of treating your patients with the tried-and-trusted aflibercept molecule
,
,
,
,

In PULSAR and PHOTON, EYLEA® 8mg demonstrated a safety profile consistent with EYLEA® 2mg from baseline through Week 96:,,,,*

Safety profile

*EYLEA® (aflibercept) 2mg was dosed at fixed Q8 intervals after 3 (nAMD) or 5 (DME) initial monthly injections.,

PULSAR safety

Adverse events in patients receiving EYLEA® 8mg were consistent with EYLEA® 2mg
,

PULSAR: most frequent AEs through Week 48

safety-profile_PULSAR-safety_Adverse-events-at-Week-48

Adapted from Korobelnik J-F. 2022.

*Any ocular treatment-emergent AE in the study eye.     
†Treatment-emergent events.      
‡All events.

PHOTON safety

Adverse events in patients receiving EYLEA® 8mg were consistent with EYLEA® 2mg
,

PHOTON: most frequent AEs through Week 48

safety-profile_PHOTON-safety_Adverse-events-at-Week-48

Adapted from Do D. 2023.

*Any ocular treatment-emergent AE in the study eye.    
†Treatment-emergent events.     
‡All events.

    2Q8, 2mg every 8 weeks. 8Q12, 8mg every 12 weeks. 8Q16, 8mg every 16 weeks. AE, adverse event. APTC, Anti-Platelet Trialists’ Collaboration. DME, diabetic macular edema. IOI, intraocular inflammation. IOP, intraocular pressure. MoA, mechanism of action. nAMD, neovascular (wet) age-related macular degeneration. Q8, every 8 weeks. SAE, serious adverse event. SAF, safety analysis set. TEAE, treatment-emergent adverse event.

PP-EYL_8mg-IL-0021-1

    • 1
      Korobelnik J-F. Intravitreal aflibercept 8mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation.
    • 2
      Do D. Aflibercept 8mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation.
    • 3
      Korobelnik J-F. Aflibercept 8mg in patients with neovascular age-related macular degeneration: Phase 3 PULSAR trial 96-week results. AAO. 3–6 November 2023. San Francisco, USA. Oral presentation.
    • 4
      Wykoff CC. Aflibercept 8mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.
    • 5
      EYLEA® 8mg SmPC as approved by the Israeli MoH.
    • 6
      Lanzetta P,
      et al
      . Intravitreal aflibercept 8mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation.